{"log_id": 7557092912081153196, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.001934, "average": 0.982083, "min": 0.788892}, "location": {"width": 813, "top": 226, "height": 29, "left": 208}, "words": "化相似(富马酸替诺福韦二吡呋酯组为-2.8%±3.5,司他夫定组为-2.4%±4.5)。两"}, {"probability": {"variance": 8.4e-05, "average": 0.997201, "min": 0.942116}, "location": {"width": 826, "top": 257, "height": 28, "left": 211}, "words": "个治疗组中,骨密度的下降大部分发生在试验的前24~48周,直至第144周,下降保"}, {"probability": {"variance": 3e-06, "average": 0.998968, "min": 0.992373}, "location": {"width": 820, "top": 286, "height": 27, "left": 209}, "words": "持稳定。接受富马酸替诺福韦二吡呋酯治疗的受试者中有28%,接受司他夫定治疗的"}, {"probability": {"variance": 1.7e-05, "average": 0.995389, "min": 0.991253}, "location": {"width": 43, "top": 223, "height": 102, "left": 1129}, "words": "品品"}, {"probability": {"variance": 0.000783, "average": 0.992657, "min": 0.822945}, "location": {"width": 829, "top": 316, "height": 27, "left": 210}, "words": "受试者中有21%的受试者腰椎的骨密度丢失至少5%或髋部的骨密度丢失最少7%。富"}, {"probability": {"variance": 2e-06, "average": 0.998924, "min": 0.993431}, "location": {"width": 817, "top": 343, "height": 29, "left": 209}, "words": "马酸替诺福韦二吡呋酯组中有4名受试者、司他夫定组中有6名受试者报告了临床上"}, {"probability": {"variance": 0.000114, "average": 0.996139, "min": 0.951806}, "location": {"width": 820, "top": 374, "height": 26, "left": 208}, "words": "相关的骨折(手指和脚趾除外)。此外,相对于司他夫定组,富马酸替诺福韦二吡呋"}, {"probability": {"variance": 4e-06, "average": 0.998622, "min": 0.991241}, "location": {"width": 829, "top": 403, "height": 26, "left": 207}, "words": "酯组中骨代谢的生化标记物(血清骨特异性碱性磷酸酶、血清降钙素、血清羧基端肽"}, {"probability": {"variance": 6e-06, "average": 0.998566, "min": 0.986851}, "location": {"width": 821, "top": 433, "height": 25, "left": 207}, "words": "尿氨基端肽)显著升高,提示骨转化增加。富马酸替诺福韦二吡呋酯组中血清甲状旁"}, {"probability": {"variance": 1.3e-05, "average": 0.998278, "min": 0.979529}, "location": {"width": 822, "top": 461, "height": 28, "left": 207}, "words": "腺激素水平和1,25维生素D水平也较高。除了骨特异性碱性磷酸酶以外,这些变化"}, {"probability": {"variance": 1e-06, "average": 0.999284, "min": 0.995579}, "location": {"width": 247, "top": 490, "height": 27, "left": 207}, "words": "结果都保持在正常范围内"}, {"probability": {"variance": 0.000256, "average": 0.992746, "min": 0.940922}, "location": {"width": 235, "top": 541, "height": 26, "left": 214}, "words": "12或12岁以上儿童患者"}, {"probability": {"variance": 5e-06, "average": 0.998983, "min": 0.987053}, "location": {"width": 826, "top": 593, "height": 28, "left": 212}, "words": "12岁至18岁以下慢性乙肝儿童受试者中实施的一项临床试验(研究115)显示,富马"}, {"probability": {"variance": 1.1e-05, "average": 0.998604, "min": 0.980692}, "location": {"width": 825, "top": 622, "height": 27, "left": 210}, "words": "酸替诺福韦二吡呋酯和安慰剂治疗组在72周内平均腰椎BMD均整体出现升高,与青少"}, {"probability": {"variance": 1.8e-05, "average": 0.997813, "min": 0.978937}, "location": {"width": 808, "top": 651, "height": 29, "left": 209}, "words": "年人群预期结果一样。富马酸替诺福韦二吡呋酯治疗组受试者基线至第72周的腰椎"}, {"probability": {"variance": 7e-06, "average": 0.997764, "min": 0.988826}, "location": {"width": 785, "top": 680, "height": 26, "left": 215}, "words": "MD和全身BMD(分别为+5%和+3%)低于安慰剂组受试者的BMD(分别为+8%和+5%)"}, {"probability": {"variance": 1.1e-05, "average": 0.998307, "min": 0.983509}, "location": {"width": 807, "top": 708, "height": 27, "left": 208}, "words": "富马酸替诺福韦二吡呋酯组三名受试者和安慰剂组两名受试者在第72周时出现显著"}, {"probability": {"variance": 2.7e-05, "average": 0.997741, "min": 0.968482}, "location": {"width": 815, "top": 736, "height": 28, "left": 218}, "words": "(大于4%)腰椎BMD丢失。基线时,富马酸替诺福韦二吡呋酯随机入组受试者的平均"}, {"probability": {"variance": 0.000902, "average": 0.990675, "min": 0.839082}, "location": {"width": 806, "top": 765, "height": 27, "left": 214}, "words": "MDZ评分显示,腰椎为-0.43,全身为-0.20,随机入组安慰剂组的平均BMDZ评分"}, {"probability": {"variance": 0.000924, "average": 0.989681, "min": 0.842172}, "location": {"width": 804, "top": 795, "height": 27, "left": 210}, "words": "显示,腰椎为-0.28,全身为-0.26。富马酸替诺福韦二吡呋酯治疗72周的受试者中"}, {"probability": {"variance": 0.001551, "average": 0.989755, "min": 0.747538}, "location": {"width": 802, "top": 824, "height": 27, "left": 213}, "words": "MDZ评分平均变化显示,腰椎-0.05,全身-0.15,安慰剂组受试者分别为+0.07和"}, {"probability": {"variance": 5.9e-05, "average": 0.996245, "min": 0.96572}, "location": {"width": 711, "top": 854, "height": 28, "left": 214}, "words": "0.06。与HIV感染的儿童患者研究结果一样,骨骼生长(身高)未受影响"}, {"probability": {"variance": 1.7e-05, "average": 0.997199, "min": 0.980749}, "location": {"width": 818, "top": 904, "height": 28, "left": 210}, "words": "富马酸替诺福韦二吡呋酯相关的骨密度和生化标记物变化对长期骨健康和未来骨折风"}, {"probability": {"variance": 3e-06, "average": 0.998522, "min": 0.994969}, "location": {"width": 177, "top": 934, "height": 26, "left": 209}, "words": "险的影响仍然未知"}, {"probability": {"variance": 2e-06, "average": 0.999147, "min": 0.991251}, "location": {"width": 819, "top": 982, "height": 29, "left": 209}, "words": "曾经报道过与使用富马酸替诺福韦二吡呋酯有关的骨软化症(与近端肾小管病变有关"}, {"probability": {"variance": 2.6e-05, "average": 0.996459, "min": 0.980993}, "location": {"width": 564, "top": 1011, "height": 28, "left": 210}, "words": "并可能造成骨折)病例。(参见“不良反应,上市后经验”)"}, {"probability": {"variance": 5e-06, "average": 0.997581, "min": 0.993151}, "location": {"width": 135, "top": 1053, "height": 26, "left": 209}, "words": "脂肪重新分布"}, {"probability": {"variance": 0.001242, "average": 0.989188, "min": 0.842146}, "location": {"width": 807, "top": 1099, "height": 29, "left": 209}, "words": "接受抗逆转录病毒联合治疗的HIV感染患者中,曾经观察到体脂重新分布/堆积包括"}, {"probability": {"variance": 4e-06, "average": 0.998987, "min": 0.990064}, "location": {"width": 820, "top": 1128, "height": 28, "left": 209}, "words": "向心性肥胖、项背脂肪增加(水牛背)、周围消瘦、面部消瘦、胸部增大和柯兴氏样"}, {"probability": {"variance": 3.6e-05, "average": 0.997532, "min": 0.972728}, "location": {"width": 685, "top": 1157, "height": 28, "left": 209}, "words": "面容。这些现象发生的机制和长期后果目前未明确。因果关系尚未确立"}, {"probability": {"variance": 1e-06, "average": 0.998897, "min": 0.996196}, "location": {"width": 156, "top": 1207, "height": 28, "left": 212}, "words": "免疫重建综合征"}, {"probability": {"variance": 7.6e-05, "average": 0.995878, "min": 0.956529}, "location": {"width": 825, "top": 1256, "height": 29, "left": 209}, "words": "接受包括富马酸替诺福韦二吡呋酯在内抗逆转录病毒联合治疗的HIV感染患者中,曾"}, {"probability": {"variance": 4e-06, "average": 0.999135, "min": 0.988567}, "location": {"width": 818, "top": 1286, "height": 27, "left": 209}, "words": "经报告过免疫重建综合征。在抗逆转录病毒联合治疗的初期,免疫系统应答的患者有"}, {"probability": {"variance": 3.9e-05, "average": 0.997431, "min": 0.966456}, "location": {"width": 823, "top": 1316, "height": 27, "left": 209}, "words": "可能对顽固性或残余的机会性感染(例如鸟结核分枝杆菌感染、巨细胞病毒、肺孢子"}, {"probability": {"variance": 1.5e-05, "average": 0.997954, "min": 0.98325}, "location": {"width": 736, "top": 1344, "height": 27, "left": 218}, "words": "肺炎(PCP),或结核)产生炎症性应答,对此有必要更进一步评价和治疗"}], "language": 3}